The Department of Health has welcomed the arrival of South Africa’s first shipment of Lenacapavir, a new HIV prevention medicine. Close to 38,000 doses of the six-monthly injectable have landed in the country, marking a significant milestone in the fight against HIV.

Lenacapavir offers a new option for people who find it difficult to access or use existing prevention methods. By providing a twice-yearly injection, the treatment aims to improve adherence and provide continuous protection, particularly for vulnerable groups such as young women, sex workers, and men who have sex with men.

“The department will, in the next few weeks, announce the official launch of this game changer, where the phased implementation plan will be outlined,” said department spokesperson Foster Mohale. “Lenacapavir is preventive medicine, not a vaccine, and is considered one of the most exciting HIV prevention advances in years.”

Health authorities say the injectable will play a key role in reducing new HIV infections and supporting South Africa’s goal of ending AIDS as a public health threat by 2030. The medicine complements existing prevention strategies, such as condoms, pre-exposure prophylaxis (PrEP), and awareness campaigns, offering a long-acting solution for those who struggle with daily or oral medication.

The introduction of Lenacapavir reflects ongoing efforts by the Department of Health to expand access to innovative HIV prevention tools. The phased rollout will ensure that the injection reaches the populations that need it most while monitoring its impact on infection rates across the country.